Last reviewed · How we verify
YPEG-Somatropin
At a glance
| Generic name | YPEG-Somatropin |
|---|---|
| Sponsor | Xiamen Amoytop Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial of YPEG-rhGH in Children With Short Stature (PHASE2)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YPEG-Somatropin CI brief — competitive landscape report
- YPEG-Somatropin updates RSS · CI watch RSS
- Xiamen Amoytop Biotech Co., Ltd. portfolio CI